US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 18:20:57 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Shohei Ohtani's first walk
Next:US overdose deaths dropped in 2023, the first time since 2018
You may also like
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East
- Mexican and Guatemalan presidents meet at border to discuss migration, security and development
- Attorney John Eastman pleads not guilty to felony charges in Arizona’s fake elector case
- Protect yourself from ticks with these tips
- Kristin Cavallari, 37, ignores critics of her age
- New Jersey overall gambling revenue up 10.4% in April, but in
- Closing prices for crude oil, gold and other commodities
- Zverev produces a comeback win over Tabilo to earn a spot in the Italian Open final
- Tom Brady and Jay